Dexamethasone Treatment Options in Canada

A collection of 294 research studies where Dexamethasone is the interventional treatment. These studies are located in the Canada . Dexamethasone is used for conditions such as Multiple Myeloma, Postoperative Pain and Lymphoma.

Home

Canada

All Treatments

Dexamethasone

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease

NCT05986318

Recruiting

In this double-blind phase II randomized controlled trial, patients with lung cancer or ≤2 oligometastatic pulmonary lesions and a concomitant diagnosis of ILD who are planned for radical Radiation Therapy (RT) will be randomized using a 2 x 2 factorial design to oral N-acetylcysteine (NAC) versus placebo, and also to short course corticosteroids versus placebo.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/23/2025

Locations: London Regional Cancer Program, London Health Sciences Centre, London, Ontario +1 locations

Conditions: Lung Cancer, Interstitial Lung Disease

Learn More ›

Steroid Injection for Sickle Cell Arthropathy Pain Therapy

NCT05983055

Completed

Sickle cell disease (SCD) is associated with arthropathy. Arthropathy may require periarticular corticosteroid injection therapy. This observational study examines efficacy, and safety of steroid injections in SCD patients. Data collection includes patient's gender, age, race, smoking history, alcohol intake, analgesic use, pain score, sleep quality, limb joint injections, post-injection analgesia, and post-injection complication. Pain is measured using numeric pain scale. Sleep quality is measu... Read More

Gender:

ALL

Ages:

Between 20 years and 99 years

Trial Updated:

01/23/2025

Locations: Salem Anaesthesia Pain Clinic, Surrey, British Columbia

Conditions: Sickle Cell Disease, Sickle Cell Abnormality

Learn More ›

Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients

NCT02990338

Completed

Primary Objective: To demonstrate the benefit of isatuximab in combination with pomalidomide and low-dose dexamethasone in the prolongation of Progression Free Survival (PFS) as compared to pomalidomide and low-dose dexamethasone in participants with refractory or relapsed and refractory multiple myeloma (MM). Secondary Objectives: * To evaluate the Overall Response Rate (ORR) as per International Myeloma Working Group (IMWG) criteria in each arm. * To compare the Overall Survival (OS) betwee... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/16/2025

Locations: BRCR Medical Center Inc. Site Number : 8400002, Plantation, Florida +110 locations

BRCR Medical Center Inc. Site Number : 8400002, Plantation, Florida

Dana Farber Site Number : 8400006, Boston, Massachusetts

Investigational Site Number : 0360004, St Leonards, New South Wales

Investigational Site Number : 0360001, Waratah, New South Wales

Investigational Site Number : 0360005, Melbourne, Victoria

Investigational Site Number : 0360002, Melbourne, Victoria

Investigational Site Number : 0360006, Richmond, Victoria

Investigational Site Number : 0560003, Antwerpen, Not set

Investigational Site Number : 0560002, Brussel, Not set

Investigational Site Number : 0560004, Gent, Not set

Investigational Site Number : 0560001, Leuven, Not set

Investigational Site Number : 1240001, Montreal, Quebec

Investigational Site Number : 1240004, Montreal, Quebec

Investigational Site Number : 1240005, Sherbrooke, Quebec

Investigational Site Number : 2030005, Brno, Not set

Investigational Site Number : 2030004, Hradec Kralove, Not set

Investigational Site Number : 2030001, Olomouc, Not set

Investigational Site Number : 2030002, Ostrava - Poruba, Not set

Investigational Site Number : 2030003, Praha 2, Not set

Investigational Site Number : 2080002, Ålborg, Not set

Investigational Site Number : 2500021, Bayonne, Not set

Investigational Site Number : 2500008, Caen, Not set

Investigational Site Number : 2500009, Dijon, Not set

Investigational Site Number : 2500017, Grenoble, Not set

Investigational Site Number : 2500013, La Roche Sur Yon, Not set

Investigational Site Number : 2500003, Lille, Not set

Investigational Site Number : 2500023, Limoges, Not set

Investigational Site Number : 2500019, Montpellier Cedex, Not set

Investigational Site Number : 2500002, Nantes, Not set

Investigational Site Number : 2500015, Paris, Not set

Investigational Site Number : 2500016, Paris, Not set

Investigational Site Number : 2500005, Pessac, Not set

Investigational Site Number : 2500004, Pierre Benite, Not set

Investigational Site Number : 2500007, POITIERS Cedex, Not set

Investigational Site Number : 2500025, Reims, Not set

Investigational Site Number : 2500014, Rennes, Not set

Investigational Site Number : 2500001, TOULOUSE Cedex 9, Not set

Investigational Site Number : 2500012, Tours, Not set

Investigational Site Number : 2500018, Vandoeuvre-les-nancy, Not set

Investigational Site Number : 2760001, Leipzig, Not set

Investigational Site Number : 3000002, Athens, Not set

Investigational Site Number : 3000005, Athens, Not set

Investigational Site Number : 3000001, Athens, Not set

Investigational Site Number : 3000004, Patra, Not set

Investigational Site Number : 3000003, Thessaloniki, Not set

Investigational Site Number : 3480001, Budapest, Not set

Investigational Site Number : 3480003, Budapest, Not set

Investigational Site Number : 3480002, Debrecen, Not set

Investigational Site Number : 3800001, Bologna, Not set

Investigational Site Number : 3800010, Catania, Not set

Investigational Site Number : 3800009, Firenze, Not set

Investigational Site Number : 3800008, Genova, Not set

Investigational Site Number : 3800007, Milano, Not set

Investigational Site Number : 3800002, Milano, Not set

Investigational Site Number : 3800006, Padova, Not set

Investigational Site Number : 3800004, Terni, Not set

Investigational Site Number : 3800003, Torino, Not set

Investigational Site Number : 3920001, Nagoya-shi, Aichi

Investigational Site Number : 3920005, Shibukawa-shi, Gunma

Investigational Site Number : 3920004, Sapporo-shi, Hokkaido

Investigational Site Number : 3920006, Kyoto-shi, Kyoto

Investigational Site Number : 3920008, Suwa-shi, Nagano

Investigational Site Number : 3920003, Okayama-shi, Okayama

Investigational Site Number : 3920007, Sunto-gun, Shizuoka

Investigational Site Number : 3920002, Shibuya-ku, Tokyo

Investigational Site Number : 4100007, Hwasun-gun, Jeollanam-do

Investigational Site Number : 4100001, Seoul, Seoul-teukbyeolsi

Investigational Site Number : 4100002, Seoul, Seoul-teukbyeolsi

Investigational Site Number : 4100006, Incheon, Not set

Investigational Site Number : 4100005, Seoul, Not set

Investigational Site Number : 5540001, Takapuna, Auckland

Investigational Site Number : 5540004, Dunedin, Otago

Investigational Site Number : 5540003, Hamilton, Waikato

Investigational Site Number : 5540002, Auckland, Not set

Investigational Site Number : 5780001, Oslo, Not set

Investigational Site Number : 6160003, Lublin, Lubuskie

Investigational Site Number : 6160005, Krakow, Malopolskie

Investigational Site Number : 6160001, Warszawa, Mazowieckie

Investigational Site Number : 6160002, Chorzow, Slaskie

Investigational Site Number : 6200004, Coimbra, Not set

Investigational Site Number : 6200002, Lisboa, Not set

Investigational Site Number : 6200001, Porto, Not set

Investigational Site Number : 6430004, Moscow, Not set

Investigational Site Number : 6430001, Moscow, Not set

Investigational Site Number : 6430002, Moscow, Not set

Investigational Site Number : 7030001, Bratislava, Not set

Investigational Site Number : 7240005, Santiago de Compostela, A Coruña [La Coruña]

Investigational Site Number : 7240001, Barcelona, Barcelona [Barcelona]

Investigational Site Number : 7240006, Santander, Cantabria

Investigational Site Number : 7240002, Pamplona, Navarra

Investigational Site Number : 7240003, Madrid, Not set

Investigational Site Number : 7240004, Salamanca, Not set

Investigational Site Number : 7520004, Luleå, Not set

Investigational Site Number : 7520005, Uddevalla, Not set

Investigational Site Number : 1580004, Kaohsiung, Not set

Investigational Site Number : 1580002, Taichung, Not set

Investigational Site Number : 1580001, Taipei, Not set

Investigational Site Number : 1580003, Taoyuan, Not set

Investigational Site Number : 7920001, Ankara, Not set

Investigational Site Number : 7920002, Antalya, Not set

Investigational Site Number : 7920005, Istanbul, Not set

Investigational Site Number : 7920006, Istanbul, Not set

Investigational Site Number : 7920003, Istanbul, Not set

Investigational Site Number : 7920004, Istanbul, Not set

Investigational Site Number : 7920008, Izmir, Not set

Investigational Site Number : 7920010, Izmir, Not set

Investigational Site Number : 7920009, Kayseri, Not set

Investigational Site Number : 7920007, Kocaeli, Not set

Investigational Site Number : 8260002, London, London, City Of

Investigational Site Number : 8260003, London, London, City Of

Investigational Site Number : 8260001, London, London, City Of

Conditions: Plasma Cell Myeloma

Learn More ›

Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients

NCT03275285

Completed

The purpose of this study it to compare the efficacity of isatuximab when combined to carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with multiple myeloma already treated with 1 to 3 prior lines of therapy.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/10/2025

Locations: UCSF MS Center Site Number : 8400002, San Francisco, California +69 locations

UCSF MS Center Site Number : 8400002, San Francisco, California

Spartanburg Medical Center Site Number : 8400003, Spartanburg, South Carolina

Investigational Site Number : 0360005, Blacktown, New South Wales

Investigational Site Number : 0360006, Tweed Heads, New South Wales

Investigational Site Number : 0360002, Wollongong, New South Wales

Investigational Site Number : 0360001, Fitzroy, Victoria

Investigational Site Number : 0360004, Heidelberg West, Victoria

Investigational Site Number : 0360007, Nedlands, Western Australia

Investigational Site Number : 0360008, West Perth, Western Australia

Hospital Sao Rafael - Rede D'OR Sao Luiz Site Number : 0760005, Salvador, Bahia

Hospital Mae de Deus Site Number : 0760003, Porto Alegre, Rio Grande Do Sul

Hospital de Amor - Hospital do Cancer de Barretos - Fundacao Pio XII Site Number : 0760001, Barretos, São Paulo

Hospital das Clinicas de Sao Paulo Site Number : 0760002, Sao Paulo, São Paulo

Instituto COI de Educacao e Pesquisa Site Number : 0760004, Rio De Janeiro, Not set

Investigational Site Number : 1240003, Surrey, British Columbia

Investigational Site Number : 1240001, Saint John, New Brunswick

Investigational Site Number : 1240002, Montreal, Quebec

Investigational Site Number : 2030002, Brno, Not set

Investigational Site Number : 2030004, Olomouc, Not set

Investigational Site Number : 2030003, Ostrava - Poruba, Not set

Investigational Site Number : 2030001, Praha 2, Not set

Investigational Site Number : 2500003, Lille, Not set

Investigational Site Number : 2500001, Nantes, Not set

Investigational Site Number : 2500006, Paris, Not set

Investigational Site Number : 2500002, Pessac, Not set

Investigational Site Number : 2500005, Pierre Benite, Not set

Investigational Site Number : 2500004, POITIERS Cedex, Not set

Investigational Site Number : 3000002, Athens, Not set

Investigational Site Number : 3000005, Athens, Not set

Investigational Site Number : 3000001, Athens, Not set

Investigational Site Number : 3000004, Patra, Not set

Investigational Site Number : 3000003, Thessaloniki, Not set

Investigational Site Number : 3480003, Budapest, Not set

Investigational Site Number : 3480001, Budapest, Not set

Investigational Site Number : 3480004, Budapest, Not set

Investigational Site Number : 3480005, Kaposvár, Not set

Investigational Site Number : 3800003, Bologna, Not set

Investigational Site Number : 3800001, Pisa, Not set

Investigational Site Number : 3800004, Reggio Emilia, Not set

Investigational Site Number : 3800002, Torino, Not set

Investigational Site Number : 3920005, Shiwa-gun, Iwate

Investigational Site Number : 3920007, Kumamoto-shi, Kumamoto

Investigational Site Number : 3920001, Suwa-shi, Nagano

Investigational Site Number : 3920003, Sunto-gun, Shizuoka

Investigational Site Number : 3920004, Shibuya-ku, Tokyo

Investigational Site Number : 3920006, Shinjuku-ku, Tokyo

Investigational Site Number : 3920002, Yamagata-shi, Not set

Investigational Site Number : 4100006, Busan, Busan-gwangyeoksi

Investigational Site Number : 4100002, Gangnam-gu, Seoul-teukbyeolsi

Investigational Site Number : 4100001, Seoul, Seoul-teukbyeolsi

Investigational Site Number : 4100004, Seoul, Seoul-teukbyeolsi

Investigational Site Number : 4100005, Seoul, Not set

Investigational Site Number : 5540001, Auckland, Not set

Investigational Site Number : 5540002, Wellington, Not set

Investigational Site Number : 6430002, Ekaterinburg, Not set

Investigational Site Number : 6430003, Kirov, Not set

Investigational Site Number : 6430004, Novosibirsk, Not set

Investigational Site Number : 7240001, Badalona, Catalunya [Cataluña]

Investigational Site Number : 7240005, Barcelona, Catalunya [Cataluña]

Investigational Site Number : 7240002, Valencia, Valenciana, Comunidad

Investigational Site Number : 7240003, Madrid, Not set

Investigational Site Number : 7240004, Sevilla, Not set

Investigational Site Number : 7920003, Adana, Not set

Investigational Site Number : 7920001, Ankara, Not set

Investigational Site Number : 7920005, Bursa, Not set

Investigational Site Number : 7920002, Istanbul, Not set

Investigational Site Number : 7920004, Samsun, Not set

Investigational Site Number : 8260004, Plymouth, Devon

Investigational Site Number : 8260005, Leicester, Leicestershire

Investigational Site Number : 8260001, Bristol, Somerset

Conditions: Plasma Cell Myeloma

Learn More ›

Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex

NCT03715478

Active Not Recruiting

This is a Phase 1/2, multi-centre, single-arm, open-label, dose-escalation study that will evaluate the safety and efficacy of IV GSK2857916 in combination with PO pomalidomide and low-dose PO dexamethasone in subjects with relapsed and/or refractory MM.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/07/2025

Locations: Cross Cancer Institute, Edmonton, Alberta +8 locations

Conditions: Relapsed and/or Refractory Multiple Myeloma

Learn More ›

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04126200

Active Not Recruiting

B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with multiple myeloma. Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC) containing humanized anti-BCMA monoclonal antibody (mAb). This is a phase I/II, randomized, open-label, platform study designed to evaluate the effects of belantamab mafodotin in combination with other anti-cancer drugs in participants with relapsed/refractory multiple myeloma. The Platform design incorporates a single m... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/01/2025

Locations: GSK Investigational Site, Atlanta, Georgia +39 locations

GSK Investigational Site, Atlanta, Georgia

GSK Investigational Site, Indianapolis, Indiana

GSK Investigational Site, Boston, Massachusetts

GSK Investigational Site, Grand Rapids, Michigan

GSK Investigational Site, Madison, Wisconsin

GSK Investigational Site, Fitzroy, Victoria

GSK Investigational Site, Melbourne, Victoria

GSK Investigational Site, Porto Alegre, Not set

GSK Investigational Site, Salvador, Not set

GSK Investigational Site, SAo Paulo, Not set

GSK Investigational Site, Vancouver, British Columbia

GSK Investigational Site, Halifax, Nova Scotia

GSK Investigational Site, Toronto, Ontario

GSK Investigational Site, Lille, Not set

GSK Investigational Site, Villejuif Cedex, Not set

GSK Investigational Site, Frankfurt, Not set

GSK Investigational Site, Hamburg, Not set

GSK Investigational Site, Kiel, Not set

GSK Investigational Site, Leipzig, Not set

GSK Investigational Site, Athens, Not set

GSK Investigational Site, Incheon, Not set

GSK Investigational Site, Seoul, Not set

GSK Investigational Site, Ulsan, Not set

GSK Investigational Site, Ciudad de Mexico, Not set

GSK Investigational Site, Leeuwarden, Not set

GSK Investigational Site, Utrecht, Not set

GSK Investigational Site, Oslo, Not set

GSK Investigational Site, Katowice, Not set

GSK Investigational Site, Lublin, Not set

GSK Investigational Site, Moscow, Not set

GSK Investigational Site, Badalona, Not set

GSK Investigational Site, Madrid, Not set

GSK Investigational Site, PamplonaNavarra, Not set

GSK Investigational Site, Pozuelo De AlarcOn Madr, Not set

GSK Investigational Site, Falun, Not set

GSK Investigational Site, Stockholm, Not set

Conditions: Multiple Myeloma

Learn More ›

A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT03215030

Completed

The main aims of this 3-part study are as follows: Part 1: To determine any side effects from modakafusp alfa single treatment and how often they occur. The dose of modakafusp alfa will be increased a little at a time until the highest dose that does not cause harmful side effects is found. Part 2: To assess clinical activity of one or more dosing schedules of modakafusp alfa alone in participants with relapsed/refractory multiple myeloma. Dexamethasone standard dose will be administered with... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/20/2024

Locations: Highlands Oncology Group, Springdale, Arkansas +93 locations

Highlands Oncology Group, Springdale, Arkansas

Los Angeles Cancer Network - Glendale Adventist Medical Center, Glendale, California

University of California Irvine, Orange, California

Office of James R. Berenson MD, West Hollywood, California

Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut

Winship Cancer Institute of Emory University, Atlanta, Georgia

Northwestern Medicine - Northwestern Medical Group, Chicago, Illinois

Loyola University Medical Center, Maywood, Illinois

Investigative Clinical Research of Indiana, LLC, Noblesville, Indiana

June E. Nylen Cancer Center, Sioux City, Iowa

Johns Hopkins Hospital, Baltimore, Maryland

Boston Medical Center, Boston, Massachusetts

Dana Farber Cancer Institute, Boston, Massachusetts

Univeristy of Nebraska Medical Center, Omaha, Nebraska

USOR - Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada

John Theurer Cancer Center, Hackensack, New Jersey

Montefiore Medical Center, Bronx, New York

University of Rochester, Rochester, New York

Levine Cancer Center, Charlotte, North Carolina

Levine Cancer Institute - Concord, Concord, North Carolina

Duke University Medical Center, Durham, North Carolina

Gabrail Cancer Center, Canton, Ohio

The Ohio State University, Columbus, Ohio

Oregon Health and Science University, Portland, Oregon

University of Pennsylvania, Philadelphia, Pennsylvania

Baptist Cancer Center - Memphis - Walnut Grove, Memphis, Tennessee

Lumi Research, Houston, Texas

British Columbia Cancer Agency Vancouver Centre, Vancouver, British Columbia

Juravinski Cancer Centre, Hamilton, Ontario

Centre de Recherche du CHUM, Montreal, Quebec

Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec

Peking University People's Hospital, Beijing, Beijing

Peking University Third Hospital, Beijing, Beijing

Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong

Henan Cancer Hospital, Zhengzhou, Henan

Wuhan Union Hospital, Wuhan, Hubei

Zhongnan Hospital of Wuhan University, Wuhan, Hubei

Nanjing Drum Tower Hospital, Nanjing, Jiangsu

The First Affiliated Hospital of Soochow University - Suzhou First People's Hospital, Suzhou, Jiangsu

Shanghai Fourth People's Hospital, Shanghai, Shanghai

Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin

The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang

Institut de cancerologie Strasbourg Europe, Strasbourg, Alsace

Centre Hospitalier Universitaire Henri Mondor, Creteil Cedex, Ile-de-france

Hopital Saint-Antoine, Paris Cedex 12, Ile-de-france

Hopital Necker-Enfants Malades, Paris, Ile-de-france

Centre Hospitalier Universitaire de Toulouse Hopital Purpan, Toulouse, Midi-pyrenees

Hopital Saint-Vincent de Paul - Lille, Lille Cedex, NORD Pas-de-calais

Centre Hospitalier Regional Universitaire de Lille, Lille Cedex, NORD Pas-de-calais

Centre Hospitalier Universitaire Nantes - Hotel Dieu, Nantes Cedex 1, PAYS DE LA Loire

Centre Hospitalier Universitaire de Poitiers, Poitiers, Poitou-charentes

Centre Hospitalier d'Argenteuil - Centre Hospitalier Victor Dupouy, Argenteuil Cedex, Not set

Universitatsklinik Tubingen, Tuebingen, Baden-wuerttemberg

Universitatsklinikum Leipzig, Leipzig, Sachsen

Evaggelismos General Hospital, Athens, Attica

Alexandra General Hospital of Athens, Athens, Attica

University Regional General Hospital of Patras, Patra, Peloponnese

The Chaim Sheba Medical Center, Ramat Gan, Tel Aviv

Hadassah Medical Center, Jerusalem, Not set

Tel Aviv Sourasky Medical Center, Tel Aviv, Not set

AON SS Antonio e Biagio e Cesare Arrigo, Alessandria, Not set

Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Not set

Azienda Ospedaliero-Universitaria di Bologna - Policlinico Sant'Orsola-Malpighi, Bologna, Not set

Azienda Ospedaliero - Universitaria Policlinico - Vittorio Emanuele, Catania, Not set

Fondazione IRCCS Policlinico San Matteo, Pavia, Not set

Nagoya City University Hospital, Nagoya, Aichi

Ogaki Municipal Hospital, Gifu-shi, Gifu

University Hospital Kyoto Prefectural University of Medicine, Kyoto-City, Kyoto

National Hospital Organization Okayama Medical Center, Okayama-city, Okayama

Japanese Red Cross Medical Center, Tokyo, Not set

Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do

Seoul National University Hospital, Seoul, Not set

The Catholic University of Korea - Seoul St. Mary's Hospital, Seoul, Not set

Oslo Universitetssykehus-Ulleval Hospital, Oslo, Not set

Ad-Vance Medical Research, Ponce, Not set

Hospital Espanol Auxilio Mutuo, San Juan, Not set

Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona

Hospital Universitari Vall d'Hebron, Barcelona, Not set

Hospital Clinic de Barcelona, Barcelona, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario Virgen de la Arrixaca, Murcia, Not set

Hospital Universitario de Salamanca, Salamanca, Not set

Hospital Universitario Marques de Valdecilla, Santander, Not set

Tri-Service General Hospital, Taipei, Taipei CITY

National Taiwan University Hospital, Taipei, Not set

Ankara Universitesi, Yenimahalle, Ankara

Ondokuz Mayis Universitesi Tp Fakultesi, Samsun, Not set

University Hospitals Birmingham NHS Foundation Trust, Birmingham, England

Royal Cornwall Hospital NHS Trust, Cornwell, England

University College London Hospitals NHS Foundation Trust, London, England

Genesis Care - Milton Keynes, Milton Keynes, England

Oxford University Hospitals NHS Foundation Trust, Oxford, England

The Royal Marsden NHS Foundation Trust, Sutton, England

Genesis Care Windsor - Genesis Care UK Ltd., Windsor, England

Conditions: Multiple Myeloma

Learn More ›

Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

NCT03030261

Active Not Recruiting

Based on the need to improve outcomes post second autologous stem cell transplant (ASCT) for multiple myeloma (MM) and the benefits seen of maintenance treatment following initial ASCT, the natural next step is to evaluate maintenance/continuation therapy following second ASCT. Pomalidomide is active against MM cells refractory to both bortezomib and lenalidomide, making it an ideal choice for continuation therapy following second ASCT. Adding elotuzumab may increase efficacy and also the durab... Read More

Gender:

ALL

Ages:

Between 18 years and 75 years

Trial Updated:

12/16/2024

Locations: Colorado Blood Cancer Institute (Sarah Cannon), Denver, Colorado +2 locations

Conditions: Multiple Myeloma in Relapse

Learn More ›

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

NCT03374085

Active Not Recruiting

This is an open-label, multi-center, international, Phase 1/2 study to assess the safety, PK and efficacy of CC-92480 monotherapy and in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma (RRMM). All eligible subjects must be previously treated with at least 3 prior regimens including lenalidomide, pomalidomide, a proteasome inhibitor and an anti-CD38 antibody and be refractory to their last line of therapy.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/11/2024

Locations: Local Institution - 103, Duarte, California +53 locations

Local Institution - 103, Duarte, California

Local Institution - 102, Atlanta, Georgia

Local Institution - 105, Boston, Massachusetts

Local Institution - 111, Buffalo, New York

Local Institution - 104, New York, New York

Local Institution - 108, Spartanburg, South Carolina

Local Institution - 101, Nashville, Tennessee

Local Institution - 106, Houston, Texas

Local Institution - 112, Charlottesville, Virginia

Local Institution - 109, Seattle, Washington

Local Institution - 804, Camperdown, New South Wales

Local Institution - 802, Adelaide, South Australia

Local Institution - 805, Clayton, Victoria

Local Institution - 803, Melbourne, Victoria

Local Institution - 806, Fitzroy, Not set

Local Institution - 904, Antwerpen, Not set

Local Institution - 905, Gent, Not set

Local Institution - 901, Leuven, Not set

Local Institution - 902, Yvoir, Not set

Local Institution - 201, Calgary, Alberta

Local Institution - 204, London, Ontario

Local Institution - 205, Ottawa, Ontario

Local Institution - 202, Toronto, Ontario

Local Institution - 206, Montreal, Quebec

Local Institution - 203, Quebec City, Quebec

Local Institution - 503, Aarhus N, Not set

Local Institution - 501, Copenhagen, Not set

Local Institution - 502, Odense, Not set

Local Institution - 601, Helsinki, Not set

Local Institution - 001, Athens, Not set

Local Institution - 705, Chuo-ku,chiba, Not set

Local Institution - 703, Fukuoka, Not set

Local Institution - 704, Kashiwa, Not set

Local Institution - 702, Kobe-city, Not set

Local Institution - 706, Kyoto-City, Not set

Local Institution - 701, Okayama, Not set

Local Institution - 152, Seoul, Not set

Local Institution - 150, Seoul, Not set

Local Institution - 151, Seoul, Not set

Local Institution - 403, Badalona (Barcelona), Not set

Local Institution - 407, Barcelona, Not set

Local Institution - 406, Caceres, Not set

Local Institution - 404, Madrid, Not set

Local Institution - 401, Pamplona, Not set

Local Institution - 409, Pozuelo de Alarcon, Not set

Local Institution - 402, Salamanca, Not set

Local Institution - 408, Santander, Not set

Local Institution - 405, Valencia, Not set

Local Institution - 304, Plymouth, Devon

Local Institution - 306, Cardiff, Not set

Local Institution - 303, London, Not set

Local Institution - 305, Newcastle Upon Tyne, Not set

Local Institution - 302, Oxford, Not set

Local Institution - 301, Sutton, Not set

Conditions: Multiple Myeloma

Learn More ›

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

NCT03989414

Active Not Recruiting

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

11/26/2024

Locations: Local Institution - 119, Denver, Colorado +48 locations

Local Institution - 119, Denver, Colorado

Local Institution - 104, Tampa, Florida

Local Institution - 108, Atlanta, Georgia

Local Institution - 112, Chicago, Illinois

Local Institution - 107, Chicago, Illinois

Local Institution - 117, Boston, Massachusetts

Local Institution - 101, Boston, Massachusetts

Local Institution - 118, Boston, Massachusetts

Local Institution - 113, Detroit, Michigan

Local Institution - 106, Rochester, Minnesota

Hackensack University Medical Center, Hackensack, New Jersey

Local Institution - 110, Winston-Salem, North Carolina

Local Institution - 115, Columbus, Ohio

Local Institution - 114, Nashville, Tennessee

Local Institution - 116, Houston, Texas

Swedish Cancer Institute, Seattle, Washington

Local Institution - 201, Calgary, Alberta

Local Institution - 205, Edmonton, Alberta

Local Institution - 204, Halifax, Nova Scotia

Local Institution - 203, Toronto, Ontario

Local Institution - 202, Montreal, Quebec

Local Institution - 802, Brno, Not set

Local Institution - 801, Ostrava-Poruba, Not set

Local Institution - 803, Praha 2, Not set

Local Institution - 902, Odense, Not set

Local Institution - 903, Vejle, Not set

Local Institution - 703, Lille cedex, Not set

Local Institution - 705, Marseille cedex, Not set

Local Institution - 704, Nantes Cedex 01, Not set

Local Institution - 701, Toulouse Cedex 9, Not set

Local Institution - 702, Tours cedex, Not set

Local Institution - 604, Freiburg, Not set

Local Institution - 605, Hamburg, Not set

Local Institution - 601, Heidelberg, Not set

Local Institution - 602, Munchen, Not set

Local Institution - 603, Wuerzburg, Not set

Local Institution - 301, Athens, Not set

Local Institution - 404, Brescia, Not set

Local Institution - 401, Milan, Not set

Local Institution - 403, Reggio Emilia, Not set

Local Institution - 402, Torino, Not set

Local Institution - 504, Badalona, Not set

Local Institution - 508, Madrid, Not set

Local Institution - 501, Madrid, Not set

Local Institution - 506, Malaga, Not set

Local Institution - 505, Pamplona, Not set

Local Institution - 502, Salamanca, Not set

Local Institution - 503, Santander, Not set

Local Institution - 507, Valencia, Not set

Conditions: Multiple Myeloma

Learn More ›

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT01665794

Active Not Recruiting

The study will investigate the effects of adding carfilzomib to the combination of pomalidomide and dexamethasone in sequential dose escalation cohorts in patients with relapsed or refractory multiple myeloma. This portion of the study is complete. This study will also investigate the effects of adding daratumumab to the combination of carfilzomib, pomalidomide and dexamethasone.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

11/14/2024

Locations: University of Chicago Comprehensive Cancer Center, Chicago, Illinois +4 locations

Conditions: Multiple Myeloma

Learn More ›

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

NCT05405166

Active Not Recruiting

This is a randomized, multicenter, Phase 3, open-label study evaluating subcutaneous (SC) vs intravenous (IV) administration of isatuximab in combination with pomalidomide and dexamethasone (Pd) in RRMM patients (study participants) who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor (PI). Eligible participants will be randomized 1:1 into 1 of 2 study arms: Arm SC: Isatuximab SC + Pd Arm IV: Isatuximab IV + Pd Participants will be allowed to co... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

11/13/2024

Locations: Mohtaseb Cancer Center and Blood Disorders Site Number : 8400028, Bullhead City, Arizona +145 locations

Mohtaseb Cancer Center and Blood Disorders Site Number : 8400028, Bullhead City, Arizona

Arizona Oncology Associates, PC - HAL- Site Number : 8400015, Prescott Valley, Arizona

Rocky Mountain Cancer Centers, LLP- Site Number : 8400021, Aurora, Colorado

Mayo Clinic- Site Number : 8400008, Jacksonville, Florida

BRCR Medical Center Inc Site Number : 8400030, Plantation, Florida

Centre for Cancer and Blood Disorders- Site Number : 8400026, Bethesda, Maryland

Hattiesburg Clinic Site Number : 8400006, Hattiesburg, Mississippi

Comprehensive Cancer Centers of Nevada- Site Number : 8400019, Las Vegas, Nevada

Atlantic Health System Site Number : 8400005, Morristown, New Jersey

New York Oncology Hematology, P.C.- Site Number : 8400017, Albany, New York

Novant Health- Site Number : 8400014, Charlotte, North Carolina

Novant Health Forsyth Medical Center Site Number : 8400114, Winston-Salem, North Carolina

Gabrail Cancer Center Site Number : 8400027, Canton, Ohio

Oncology_Hematology Care Clinical Trials, LLC- Site Number : 8400016, Cincinnati, Ohio

Oncology Associates Of Oregon, P.C.- Site Number : 8400018, Eugene, Oregon

Spoknwrd Clinical Trials Inc. Site Number : 8400023, Easton, Pennsylvania

Gibbs Cancer Center-Spartanburg Medical Center- Site Number : 8400002, Spartanburg, South Carolina

Texas Oncology Baylor Sammons- Site Number : 8400022, Dallas, Texas

University of Texas Southwestern- Site Number : 8400024, Dallas, Texas

Lumi Research- Site Number : 8400029, Kingwood, Texas

Texas Oncology - San Antonio- Site Number : 8400020, San Antonio, Texas

George E. Wahlen Salt Lake City VA Medical Center- Site Number : 8400011, Salt Lake City, Utah

UW Cancer Center at ProHealth Care Site Number : 8400001, Waukesha, Wisconsin

Investigational Site Number : 0320007, Caba, Buenos Aires

Investigational Site Number : 0320001, Caba, Buenos Aires

Investigational Site Number : 0320002, Ciudad Autonoma Buenos Aires, Buenos Aires

Investigational Site Number : 0320006, La Plata, Buenos Aires

Investigational Site Number : 0320003, Caba, Ciudad De Buenos Aires

Investigational Site Number : 0320008, Caba, Ciudad De Buenos Aires

Investigational Site Number : 0320005, Caba, Ciudad De Buenos Aires

Investigational Site Number : 0320010, Cordoba, Córdoba

Investigational Site Number : 0320004, Buenos Aires, Not set

Investigational Site Number : 0320009, Mendoza, Not set

Investigational Site Number : 0360007, Liverpool, New South Wales

Investigational Site Number : 0360004, Waratah, New South Wales

Investigational Site Number : 0360003, Wollongong, New South Wales

Investigational Site Number : 0360008, Adelaide, South Australia

Investigational Site Number : 0360009, Fitzroy, Victoria

Investigational Site Number : 0360006, Melbourne, Victoria

Investigational Site Number : 0360001, Richmond, Victoria

NOHC - Nucleo de Oncologia e Hematologia do Ceara- Site Number : 0760006, Fortaleza, Ceará

OC ONCOCLINICAS MULTIHEMO ILHA DO LEITE Site Number : 0760007, Recife, Pernambuco

CHN - Complexo Hospitalar de Niteroi Site Number : 0760008, Niteroi, Rio De Janeiro

Hospital Mae de Deus Site Number : 0760003, Porto Alegre, Rio Grande Do Sul

Clínica São Germano- Site Number : 0760001, Sao Paulo, São Paulo

Instituto COI de Educacao e Pesquisa- Site Number : 0760004, Rio De Janeiro, Not set

Investigational Site Number : 1240001, Toronto, Ontario

Investigational Site Number : 1240004, Greenfield Park, Quebec

Investigational Site Number : 1240003, Montreal, Quebec

Investigational Site Number : 1520003, Santiago, Reg Metropolitana De Santiago

Investigational Site Number : 1520002, Santiago, Reg Metropolitana De Santiago

Investigational Site Number : 1520006, Santiago, Reg Metropolitana De Santiago

Investigational Site Number : 1520005, Viña del Mar, Valparaíso

Investigational Site Number : 1520004, Santiago, Not set

Investigational Site Number : 1520001, Temuco, Not set

Investigational Site Number : 1560001, Beijing, Not set

Investigational Site Number : 1560022, Beijing, Not set

Investigational Site Number : 1560010, Changsha, Not set

Investigational Site Number : 1560006, Guangzhou, Not set

Investigational Site Number : 1560002, Hangzhou, Not set

Investigational Site Number : 1560020, Nanchang, Not set

Investigational Site Number : 1560019, Nanning, Not set

Investigational Site Number : 1560011, Qingdao, Not set

Investigational Site Number : 1560013, Shenyang, Not set

Investigational Site Number : 1560007, Tianjin, Not set

Investigational Site Number : 1560009, Tianjin, Not set

Investigational Site Number : 1560018, Tianjin, Not set

Investigational Site Number : 1560003, Wuhan, Not set

Investigational Site Number : 1560008, Wuhan, Not set

Investigational Site Number : 1560004, Zhengzhou, Not set

Investigational Site Number : 2030005, Brno, Not set

Investigational Site Number : 2030003, Olomouc, Not set

Investigational Site Number : 2030006, Ostrava - Poruba, Not set

Investigational Site Number : 2030004, Praha 2, Not set

Investigational Site Number : 2500002, Nantes, Not set

Investigational Site Number : 2500005, Paris, Not set

Investigational Site Number : 2500008, Perigueux, Not set

Investigational Site Number : 2500001, Poitiers, Not set

Investigational Site Number : 2500009, Saint-Etienne Cedex 2, Not set

Investigational Site Number : 2500003, TOULOUSE Cedex 9, Not set

Investigational Site Number : 2500007, Tours, Not set

Investigational Site Number : 2760005, Dresden, Not set

Investigational Site Number : 2760001, Hamburg, Not set

Investigational Site Number : 2760003, Heidelberg, Not set

Investigational Site Number : 2760006, Lübeck, Not set

Investigational Site Number : 2760007, Nürnberg, Not set

Investigational Site Number : 3000002, Athens, Not set

Investigational Site Number : 3000001, Athens, Not set

Investigational Site Number : 3000005, Ioannina, Not set

Investigational Site Number : 3000003, Patra, Not set

Investigational Site Number : 3000004, Thessaloniki, Not set

Investigational Site Number : 3480002, Budapest, Not set

Investigational Site Number : 3480004, Budapest, Not set

Investigational Site Number : 3480003, Kaposvár, Not set

Investigational Site Number : 3480008, Pécs, Not set

Investigational Site Number : 3480005, Szekesfehervar, Not set

Investigational Site Number : 3480006, Szombathely, Not set

Investigational Site Number : 3800001, Meldola, Forlì-Cesena

Investigational Site Number : 3800006, Rome, Roma

Investigational Site Number : 3800004, Ancona, Not set

Investigational Site Number : 3800002, Bologna, Not set

Investigational Site Number : 3800005, Brescia, Not set

Investigational Site Number : 3800007, Napoli, Not set

Investigational Site Number : 3800008, Palermo, Not set

Investigational Site Number : 3800003, Pavia, Not set

Investigational Site Number : 3920001, Nagoya-shi, Aichi

Investigational Site Number : 3920007, Kamogawa-shi, Chiba

Investigational Site Number : 3920005, Higashiibaraki-gun, Ibaraki

Investigational Site Number : 3920010, Shiwa-gun, Iwate

Investigational Site Number : 3920012, Kamakura-shi, Kanagawa

Investigational Site Number : 3920003, Kyoto-shi, Kyoto

Investigational Site Number : 3920006, Natori-shi, Miyagi

Investigational Site Number : 3920002, Okayama-shi, Okayama

Investigational Site Number : 3920011, Osaka-shi, Osaka

Investigational Site Number : 3920008, Sunto-gun, Shizuoka

Investigational Site Number : 3920004, Shibuya-ku, Tokyo

Investigational Site Number : 3920009, Yamagata-shi, Not set

Investigational Site Number : 5780001, Oslo, Not set

Investigational Site Number : 5780002, Ålesund, Not set

Investigational Site Number : 6160004, Wroclaw, Dolnoslaskie

Investigational Site Number : 6160005, Krakow, Malopolskie

Investigational Site Number : 6160001, Lublin, Not set

Investigational Site Number : 7240003, Santander, Cantabria

Investigational Site Number : 7240004, Badalona, Catalunya [Cataluña]

Investigational Site Number : 7240007, Madrid, Madrid, Comunidad De

Investigational Site Number : 7240001, Pamplona, Navarra

Investigational Site Number : 7240005, Madrid, Not set

Investigational Site Number : 7240006, Murcia, Not set

Investigational Site Number : 7240002, Salamanca, Not set

Investigational Site Number : 7520001, Borås, Not set

Investigational Site Number : 7520003, Stockholm, Not set

Investigational Site Number : 1580001, Kaohsiung, Not set

Investigational Site Number : 1580005, Tainan, Not set

Investigational Site Number : 1580002, Taipei, Not set

Investigational Site Number : 7920007, Ankara, Not set

Investigational Site Number : 7920009, Ankara, Not set

Investigational Site Number : 7920004, Bornova, Not set

Investigational Site Number : 7920003, Istanbul, Not set

Investigational Site Number : 7920005, Istanbul, Not set

Investigational Site Number : 7920008, Istanbul, Not set

Investigational Site Number : 7920001, Istanbul, Not set

Investigational Site Number : 8260002, Leicester, Leicestershire

Investigational Site Number : 8260005, London, London, City Of

Investigational Site Number : 8260001, Norwich, Norfolk

Investigational Site Number : 8260004, Birmingham, Not set

Investigational Site Number : 8260003, Derby, Not set

Conditions: Plasma Cell Myeloma Recurrent

Learn More ›